Results for
"[search-keyword]"
Sponsor content
176 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Ebglyss (lebrikizumab) has been approved to treat severe atopic dermatitis in adult and adolescent patients.
-
Australian Public Assessment Report (AusPAR)Mounjaro (tirzepatide) has been approved, as an adjunct to a reduced-calorie diet and increased physical activity, for chronic weight management.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALTZ ixekizumab 80 mg/mL solution for injection prefilled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALTZ ixekizumab 80 mg/mL solution for injection prefilled syringe.
-
Prescription medicine registrationActive ingredients: tirzepatide.
-
Sep-2024Prescription medicine evaluationActive ingredient: tirzepatide.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 20.83 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 25 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 8.33 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 4.17 mg/mL solution for injection multidose pre-filled pen.